Inflammation in pulmonary arterial hypertension

Chest

Volumn 141, Issue 1, 2012, Pages 210-221

  Price, Laura C ^a,b,c,d   Wort, S John ^d   Perros, Frédéric ^a,b,c   Dorfmüller, Peter ^a,b,c   Huertas, Alice ^a,b,c   Montani, David ^a,b,c   Cohen Kaminsky, Sylvia ^a,b,c   Humbert, Marc ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; AUTOANTIBODY; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; C REACTIVE PROTEIN; DEXFENFLURAMINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCROTALINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RANTES; SEROTONIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

B LYMPHOCYTE; BONE MARROW; CELL PROLIFERATION; CONNECTIVE TISSUE DISEASE; DENDRITIC CELL; DISEASE MODEL; EPSTEIN BARR VIRUS INFECTION; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXIA; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MAST CELL; MONOCYTE; MORBIDITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SCHISTOSOMIASIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84855467311     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0793     Document Type: Article

References (125)

1. Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc. 2006; 3(1):111-115.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(suppl 1):S43-S54.
3. Lane KB, Machado RD, Pauciulo MW, et al. International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000; 26(1):81-84.
4. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat. 2006; 27(2):121-132. (Pubitemid 43238027)
5. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000; 37(10): 741-745.
6. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122(2):156-163.
7. Nathan C. Points of control in inflammation. Nature. 2002; 420(6917):846-852. (Pubitemid 36019637)
8. Zernecke A, Weber C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol. 2005; 100(2):93-101. (Pubitemid 40361602)
9. Raines EW, Ferri N. Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res. 2005; 46(6):1081-1092. (Pubitemid 43109823)
10. Schober A. Chemokines in vascular dysfunction and remodeling . Arterioscler Thromb Vasc Biol. 2008; 28(11):1950-1959.
11. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009; 297(6):L1013-L1032.
12. Sahara M, Sata M, Morita T, Nakamura K, Hirata Y, Nagai R. Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation. Circulation. 2007; 115(4):509-517. (Pubitemid 46184202)
13. Perros F, Dorfmüller P, Souza R, et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J. 2007; 29(3):462-468. (Pubitemid 46372091)
14. Madjdpour C, Jewell UR, Kneller S, et al. Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2003; 284(2):L360-L367. (Pubitemid 36164371)
15. Burke DL, Frid MG, Kunrath CL, et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol. 2009; 297(2):L238-L250.
16. Frid MG, Brunetti JA, Burke DL, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol. 2006; 168(2):659-669. (Pubitemid 43271163)
17. Hong KH, Lee YJ, Lee E, et al. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation. 2008; 118(7):722-730.
18. Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J. 2008; 31(1):135-139.
19. Marecki JC, Cool CD, Parr JE, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef -infected macaques. Am J Respir Crit Care Med. 2006; 174(4):437-445. (Pubitemid 44223125)
20. Crosby A, Jones FM, Southwood M, et al. Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med. 2010; 181(3):279-288.
21. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med. 2007; 175(12):1280-1289. (Pubitemid 46905754)
22. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodefi- ciency virus infection. Hum Pathol. 1997; 28(4):434-442. (Pubitemid 27175084)
23. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994; 144(2):275-285. (Pubitemid 24165948)
24. Hall S, Brogan P, Haworth SG, Klein N. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax. 2009; 64(9):778-783.
25. Pinto RF, Higuchi Mde L, Aiello VD. Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. Cardiovasc Pathol. 2004; 13(5): 268-275. (Pubitemid 39195211)
26. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958; 18(4 Part 1):533-547.
27. Perros F, Dorfmüller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension . Am J Resp Crit Care Med. In press.
28. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol. 1991; 44(12):1003-1006.
29. Mitani Y, Ueda M, Maruyama K, et al. Mast cell chymase in pulmonary hypertension. Thorax. 1999; 54(1):88-90. (Pubitemid 29103760)
30. Hamada H, Terai M, Kimura H, Hirano K, Oana S, Niimi H. Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am J Respir Crit Care Med. 1999; 160(4):1303-1308. (Pubitemid 29487474)
31. Le Pavec J, Montani BGD, Perros F, Savale L, Simonneau G, Sitbon O, Humbert. Circulating dendritic cells in idiopathic pulmonary arterial Hypertension and cirrhotic portopulmonary hypertension. Am J Respir Crit Care Med. 2009; 179(1):A4289.
32. Montani D, Perros F, Gambaryan N, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011; 184(1):116-123.
33. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995; 151(5):1628-1631.
34. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010; 122(9):920-927.
35. Sanchez O, Marcos E, Perros F, et al. Role of endotheliumderived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2007; 176(10):1041-1047. (Pubitemid 350127849)
36. Dorfmüller P, Zarka V, Durand-Gasselin I, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165(4):534-539. (Pubitemid 34165478)
37. Balabanian K, Foussat A, Dorfmüller P, et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165(10):1419-1425. (Pubitemid 34522947)
38. Diller GP, van Eijl S, Okonko DO, et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation. 2008; 117(23):3020-3030.
39. Okawa-Takatsuji M, Aotsuka S, Uwatoko S, Kinoshita M, Sumiya M. 1999. Increase of cytokine production by pulmonary artery endothelial cells induced by supernatants from monocytes stimulated with autoantibodies against U1-ribonucleoprotein. Clin Exp Rheumatol. 1999; 17(6): 705-712.
40. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998; 11(3):554-559. (Pubitemid 28194842)
41. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011; 365(1):44-53.
42. Niu X, Nouraie M, Campbell A, et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS ONE. 2009; 4(11):e7956.
43. Lesprit P, Godeau B, Authier FJ, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines . Am J Respir Crit Care Med. 1998; 157(3 pt 1):907-911.
44. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52(12):3792-3800. (Pubitemid 41798217)
45. Asherson RA. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol. 1990; 17(3):414-415. (Pubitemid 20106633)
46. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis. 2002; 45(3):225-234. (Pubitemid 36139818)
47. Thurnheer R, Jenni R, Russi EW, Greminger P, Speich R. Hyperthyroidism and pulmonary hypertension. J Intern Med. 1997; 242(2):185-188.
48. Montani D, Achouh L, Marcelin AG, et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J. 2005; 26(5):969-972. (Pubitemid 41632055)
49. Kawut SM, Krowka MJ, Trotter JF, et al. Pulmonary Vascular Complications of Liver Disease Study Group. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008; 48(1):196-203. (Pubitemid 351975544)
50. Karmochkine M, Wechsler B, Godeau P, Brenot F, Jagot JL, Simonneau G. Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis. 1996; 55(8): 561-562. (Pubitemid 26249043)
51. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol. 2002; 29(2):282-287. (Pubitemid 34118774)
52. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008; 58(2):521-531. (Pubitemid 351294886)
53. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006; 130(1):182-189. (Pubitemid 44116858)
54. Jouve P, Humbert M, Chauveheid MP, Jaïs X, Papo T. POEMS syndrome-related pulmonary hypertension is steroid-responsive . Respir Med. 2007; 101(2):353-355. (Pubitemid 46075967)
55. Zuber JP, Calmy A, Evison JM, et al. Swiss HIV Cohort Study Group. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis. 2004; 38(8): 1178-1185. (Pubitemid 38951268)
56. Barnier A, Frachon I, Dewilde J, Gut-Gobert C, Jobic Y, Leroyer C. Improvement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapy. Eur Respir J. 2009; 34(1):277-278.
57. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS. 2010; 24(1):67-75.
58. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008; 177(1):108-113.
59. Song Y, Coleman L, Shi J, et al. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J Physiol Heart Circ Physiol. 2008; 295(2):H677-H690.
60. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003; 167(10):1433-1439. (Pubitemid 36609730)
61. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest. 2000; 118(4):1133-1141.
62. Humbert M. Mediators involved in HIV-related pulmonary arterial hypertension. AIDS. 2008; 22(suppl 3):S41-S47.
63. Ascherl G, Hohenadl C, Schatz O, et al. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy . Blood. 1999; 93(12):4232-4241. (Pubitemid 29279265)
64. Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J Leukoc Biol. 2006; 79(1):192-201. (Pubitemid 43054265)
65. Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis. 1992; 145(5):1196-1200.
66. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun. 2005; 333(4):1107-1115. (Pubitemid 40910118)
67. Voelkel NF, Cool CD, Flores S. From viral infection to pulmonary arterial hypertension: a role for viral proteins? AIDS. 2008; 22(suppl 3):S49-S53.
68. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med. 2003; 349(12):1113-1122. (Pubitemid 37122323)
69. Bull TM, Meadows CA, Coldren CD, et al. Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells. Am J Respir Cell Mol Biol. 2008; 39(6):706-716.
70. Durrington HJ, Upton PD, Hoer S, et al. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem. 2010; 285(48):37641-37649.
71. Hashimoto T, Sakata Y, Fukushima K, et al. Pulmonary arterial hypertension associated with chronic active Epstein-Barr virus infection. Intern Med. 2011; 50(2):119-124.
72. Valmary S, Dorfmüller P, Montani D, Humbert M, Brousset P, Degano B. Human γ-herpesviruses Epstein-Barr virus and human herpesvirus-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension . Chest. 2011; 139(6):1310-1316.
73. Bendayan D, Sarid R, Cohen A, Shitrit D, Shechtman I, Kramer MR. Absence of human herpesvirus 8 DNA sequences in lung biopsies from Israeli patients with pulmonary arterial hypertension. Respiration. 2008; 75(2):155-157. (Pubitemid 351363868)
74. Henke-Gendo C, Mengel M, Hoeper MM, Alkharsah K, Schulz TF. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2005; 172(12):1581-1585. (Pubitemid 43076549)
75. Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest. 2010; 137(suppl 6):20S-29S.
76. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation. 2009; 119(11):1518-1523.
77. Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009; 30(4):376-385.
78. Graham BB, Mentink-Kane MM, El-Haddad H, et al. Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am J Pathol. 2010; 177(3):1549-1561.
79. Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev. 2001; 23(2):231-247. (Pubitemid 34074111)
80. Gómez-Sánchez MA, Mestre de Juan MJ, Gómez-Pajuelo C, López JI, Díaz de Atauri MJ, Martínez-Tello FJ. Pulmonary hypertension due to toxic oil syndrome. A clinicopathologic study. Chest. 1989; 95(2):325-331. (Pubitemid 19051411)
81. Tazelaar HD, Myers JL, Drage CW, King TE Jr, Aguayo S, Colby TV. Pulmonary disease associated with L-tryptophaninduced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest. 1990; 97(5):1032-1036. (Pubitemid 20166786)
82. Perros F, Dorfmüller P, Souza R, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension . Eur Respir J. 2007; 29(5):937-943. (Pubitemid 46711898)
83. Bull TM, Coldren CD, Moore M, et al. Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension . Am J Respir Crit Care Med. 2004; 170(8):911-919. (Pubitemid 39359232)
84. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 53(14): 1211-1218.
85. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007; 8(4):345-350. (Pubitemid 46745409)
86. Daley E, Emson C, Guignabert C, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med. 2008; 205(2):361-372. (Pubitemid 351281602)
87. Ulrich S, Nicolls MR, Taraseviciene L, Speich R, Voelkel N. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration. 2008; 75(3):272-280. (Pubitemid 351450398)
88. Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol. 1986; 8(6):1307-1311. (Pubitemid 17208906)
89. Tamby MC, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax. 2005; 60(9):765-772. (Pubitemid 41297897)
90. Tamby MC, Humbert M, Guilpain P, et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J. 2006; 28(4):799-807. (Pubitemid 46332002)
91. Carvalho D, Savage CO, Black CM, Pearson JD. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest. 1996; 97(1):111-119.
92. Bordron A, Dueymes M, Levy Y, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998; 101(10):2029-2035. (Pubitemid 28244086)
93. Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P. HLA markers for susceptibility and expression in scleroderma. J Rheumatol. 2005; 32(8):1481-1487. (Pubitemid 41113968)
94. Vajner L, Vytásek R, Lachmanová V, et al. Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats. Int J Exp Pathol. 2006; 87(5):383-391. (Pubitemid 44370918)
95. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008; 9(11):1215-1223.
96. Davie NJ, Crossno JT Jr, Frid MG, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol. 2004; 286(4):L668-L678. (Pubitemid 38365049)
97. Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008; 178(1):81-88. (Pubitemid 351919196)
98. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009; 54(suppl 1):S10-S19.
99. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009; 104(2):236-244.
100. Li XQ, Wang HM, Yang CG, Zhang XH, Han DD, Wang HL. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol Sin. 2011; 32(2):217-222.
101. Barnes PJ. Nuclear factor-kappa B. I nt J Biochem Cell Biol. 1997; 29(6):867-870.
102. R aychaudhuri B, Dweik R, Connors MJ, et al. Nitric oxide blocks nuclear factor-kappaB activation in alveolar macrophages. Am J Respir Cell Mol Biol. 1999; 21(3): 311-316.
103. H agen M, Fagan K, Steudel W, et al. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2007; 292(6): L1473-L1479.
104. Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res. 2009; 104(10):1184-1191.
105. Price LC, Montani D, Tcherakian C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J. 2011; 37(4):813-822.
106. Hecker M, Zaslona Z, Kwapiszewska G, et al. Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 182(6):805-818.
107. Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A. Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells. J Allergy Clin Immunol. 2000; 105(2 pt 1):333-338. (Pubitemid 30109048)
108. Heresi GA, Aytekin M, Newman J, Dweik RA. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. Lung. 2010; 188(3): 191-197.
109. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol. 1994; 11(6):664-675.
110. Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009; 11(5):R147.
111. Eddahibi S, Chaouat A, Tu L, et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006; 3(6):475-476. (Pubitemid 44285519)
112. M iyata M, S akuma F, Y oshimura A, I shikawa H, N ishimaki T, Kasukawa R. Pulmonary hypertension in rats. 2. Role of interleukin-6. Int Arch Allergy Immunol. 1995; 108(3): 287-291.
113. Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009; 10: 6.
114. I maizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb. 2004; 11(1):15-21.
115. Bhargava A, Kumar A, Yuan N, Gewitz MH, Mathew R. Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis. 1999; 1(3):126-132.
116. L angleben D, Reid LM. Effect of methylprednisolone on monocrotaline-induced pulmonary vascular disease and right ventricular hypertrophy. Lab Invest. 1985; 52(3): 298-303.
117. B onnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A. 2007; 104(27):11418-11423.
118. Ikeda Y, Yonemitsu Y, Kataoka C, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol. 2002; 283(5):H2021-H2028. (Pubitemid 35217037)
119. Suzuki C, Takahashi M, Morimoto H, et al. Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. Biochem Biophys Res Commun. 2006; 349(2):781-788. (Pubitemid 44344582)
120. K ato T, Kitamura H, Kanisawa M. Comparative effects of isosorbide dinitrate, prednisolone, indomethacin, and elastase on the development of monocrotaline-induced pulmonary hypertension. Exp Mol Pathol. 1989; 50(3):303-315.
121. S chermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005; 115(10):2811-2821.
122. Morelli S, Giordano M, De Marzio P, Priori R, Sgreccia A, Valesini G. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus . Lupus. 1993; 2(6):367-369. (Pubitemid 24017336)
123. Le Pavec J, Humbert M, Mouthon L, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 181(12):1285-1293.
124. Katsushi H, Kazufumi N, Hideki F, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J. 2004; 68(3):227-231.
125. S trassheim D, Riddle SR, Burke DL, Geraci MW, Stenmark KR. Prostacyclin inhibits IFN-gamma-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner. J Immunol. 2009; 183(11):6981-6988.